Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized double-blind study of V116 polyvalent pneumococcal conjugate vaccine in healthy Japanese adults
jRCT2071200094Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pneumococcal 21-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by Merck & Co. Started Feb 2021; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on jRCT2071200094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200094.